Overview
Alexion (NASDAQ: ALXN)
Alexion is a global biopharmaceutical company focused on rare diseases through innovation, development and commercialisation of therapies. The company was founded in 1992 and has 2,500 employees serving patients in 50 countries around the world.
BREAKTHROUGH THERAPIES
Alexion has delivered therapies to patients suffering from rare diseases. The company has pioneered the complex field of complement biology and delivered solutions to patients with complement-mediated and metabolic disorders.
Alexion developed Soliris® (eculizumab), the world’s first approved terminal complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG).
Alexion also has two enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders—Strensiq® (asfotase alfa) for patients with hypophosphatasia (HPP) and Kanuma® (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL-D).
The company’s website can be found here.
News
-
16 Aug 2018 2 min read
IBT adds to Celgene, reduces Neurocrine in July rejig
IBT adds to Celgene, reduces Neurocrine in July rejig International Biotechnology Trust (IBT) appears to have boosted its shareholding in Celgene – which has risen by one place and ~ two NAV percentage points to become its top investee company, as part of a rejig of its largest investments in July. According to the trust’s latest […]
-
28 Jun 2018 3 min read
Key regulatory updates biotech specialist trust investees
Key regulatory updates biotech specialist trust investees Two stocks that core holdings for biotech specialist trusts have reported important regulatory updates in the past week, with several other companies approaching key events, as detailed below. Array BioPharma (Nasdaq: ARRY), a top ten holding for International Biotechnology Trust (IBT), received FDA approval for Braftovi in combination with Mektovi […]
-
15 Mar 2018 2 min read
Trust favourite Alexion notches up a success with important ‘1210 clinical data
Trust favourite Alexion notches up a success with important ‘1210 clinical data Alexion (Nasdaq: ALXN) scored an important positive result in the first of two pivotal trials with ALXN1210 in paroxysmal nocturnal hemoglobinuria (PNH), boosting its shares by around 8% earlier today. ALXN1210 is a long-acting follow-up molecule to Soliris, Alexion’s blockbuster drug for three […]
-
18 Dec 2017 1 min read
Investment Trust Insider on Biotech
Investment Trust Insider on Biotech – inspired by the launch of our biotech news service on QuotedData, I wrote something for Citywire that looks at some of the exciting stories that have been published just in the last couple of weeks. James Carthew: biotech boom boosts generalist trusts This week I am returning to the […]
-
08 Dec 2017 2 min read
Alexion stock rises on reports of activist investor
Alexion stock rises on reports of activist investor – Stock in the US rare disease specialist Alexion Pharmaceuticals is up 6% this morning on reports that the famed New York-based activist hedge fund Elliot Management has taken a stake. Elliott has reportedly threatened to initiate a proxy battle potentially to replace the relatively new management team […]
-
07 Dec 2017 1 min read
FDA OK for Alexion’s Soliris in myasthenia gravis
FDA OK for Alexion’s Soliris in myasthenia gravis US approval for Alexion’s complement inhibitor Soliris in anti-acetylcholine receptor antibody-positive generalised myasthenia gravis could double the market for a product that is already selling $3bn/year, if some of the most optimistic sell-siders are to be believed. Soliris, which is famously one of, if not the, most […]
-
21 Mar 2016 4 min read
All change again for Jupiter Global
Jupiter Global’s board has decided to seek shareholders’ approval for a change in both the company’s investment strategy and name with effect from the general meeting of shareholders which has been convened for next month. These changes are the subject of a circular which has been posted alongside the Half Year report. This is an important […]
